ECCMID Symposium: Expediting antibacterial development: core lessons and key tools for a rocky road

Dear All:

GARDP and CARB-Xed co-sponorsored yesterday an ECCMID symposium entitled “Expediting antibacterial development: core lessons and key tools for a rocky road.” A detailed tour of the many lessons we’ve learned in recent years, the program was (follow the links to download the talks):

  • Marco Cavaleri (EMA): EU regulatory tools for expedited antibacterial development programmes
    • EMA has a portfolio of regulatory tools to support expedited development of new antibacterial agents targeting unmet needs. 
    • A draft guidance on pediatric evaluation of novel antibacterials was released 22 Mar 2018, is open for comment, and will be the subject of a joint EMA-FDA-PMDA workshop on 21-22 June 2018 (you can mark your calendar now and expect an official announcement soon).
  • Sumati Nambiar (FDA): US regulatory tools for expedited antibacterial development programmes
    • Options to expedite exist and are grounded in the seriousness of the condition and the (lack of) availability of other therapeutic choices 
    • FDA is in the process of moving all Susceptibility Test Interpretive Criteria (STIC) from product labels to an online format (see also this discussion of same, the intent is be done by December of this year). Dr. Cavaleri noted that EMA is also planning to take this step.
  • Both Dr. Nambiar and Dr. Cavaleri also emphasized:
    • Early dialogue with regulators is important and is encouraged!
    • EMA and FDA have implemented a Consultative Advice approach in which Scientific Advice is requested from only one agency but the briefing materials are shared with both agencies. As the agencies have monthly mutual update teleconferences, this facilitates common feedback and may have the advantage of increasing the conversation feel of interactions relative to formal Parallel Scientific Advice.
  • William Hope (Liverpool): PK-PD in support of accelerated programmes: how much is enough?
    • It is important to use multiple models and multiple model strains.
    • You’ve done enough PK-PD studies when you would be prepared to be the first person to administer a new compound to a patient!
  • John Rex (me): Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
    • Non-traditional products (e.g., virulence inhibitors) are intriguing but must still provide standard data proving their value.
    • There are 4 archetypes for non-traditional therapeutic products (Create, Transform, Restore, and Enhance) and 4 recurring problems: Narrow-spectrum products are tricky, Standalone activity opens doors, Superiority is hard to show, and novel Endpoints may be needed but are as yet elusive.

I encourage you to download and review these talks! And if you are interested in non-traditional products, please consider attending the 14 June workshop on such products that is being organized by the Duke-Margolis Health Policy Center on behalf of FDA. And, don’t overlook the above-mentioned joint EMA-FDA-PMDA workshop on the EMA pediatric guideline for antbacterials on 21-22 June 2018.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

CDC-FDA webinar: Developing drugs to prevent healthcare-associated infections (30 Aug 2022)

Dear All, A quick note today to call your attention to an upcoming webinar that will be of wide interest. Substantial new details have been added to the online agenda materials for the 30 August 2022 (virtual, 8.30a-5.00p ET) webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very

US Senate and House / Call for Pull incentives in FY23 budget

Dear All, The US Government is now building its budget for FY23 (Federal Year 2023, really runs 1 Oct 22 to 30 Sep 23). We had proposals from the House for the Department of Health and Human Services (DHHS) budget in late June;  and the proposal from Senate was released on 28 Jul 2022. Each

WHO Vaccine pipeline review; CDC on impact of COVID on AMR

Dear All, WHO continues to crank out those pipeline reviews … now we have one for bacterial vaccines! Go here for the press release and here for the report. The report considers data from 2010 forward and (interestingly) provides data on both active and failed projects. The review identified 94 active preclinical candidates and 61

IDWeek 2022: New pipeline sessions seek presentation of therapeutics and diagnostics!

Dear All: I have learned that the program for IDWeek 2022 will have specific dedicated pipeline sessions for therapeutics and diagnostics. The online details are relatively scant, but my understanding is that the therapeutics of interest for these sessions include antibacterials, antifungals, and non-HIV, non-COVID antiviral agents. There do not appear to be any constraints

Scroll to Top